AI Robotics in Medicine

Healthcare AI is splitting between long-horizon platform bets and governed, near-term deployment. Lilly’s shares fell and sit below key averages despite an Ajax Therapeutics acquisition and a Profluent DNA‑editing collaboration, underscoring valuation and revenue‑concentration risks, while Elevance and Deloitte’s agentic AI keeps humans central yet speeds payer responses. Watch whether investors favor workflow automation that delivers faster time to value over uncertain R&D optionality, as Lilly’s bearish setup and volatility signal fragile sentiment.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

1. Eli Lilly Shares Fall Despite Oncology Buy and AI DNA-Editing Pact

Eli Lilly and Company shares pulled back, trading at $852. 88 after a 2.

39% drop, and sitting well below the 20-day ($919. 62), 50-day ($954.

26), and 200-day ($909. 37) moving averages, signaling persistent bearish momentum.

The company expanded its pipeline by agreeing to acquire Ajax Therapeutics for up to $2. 3 billion and launching a multi-program collaboration with Profluent worth up to $2.

25 billion to develop AI-designed DNA-editing medicines. Despite these moves and strong 2025 sales from Mounjaro and Zepbound—56% of revenue, $36.

5 billion combined—shares remain under heavy selling pressure, with a projected consolidation between $842. 68 and $868.

18 absent a rebound. Expert views diverge: Anton Kharitonov sees no stabilization and valuation risk from revenue concentration, while Viktoras Karapetjanc views the pullback as an opportunity for innovation-focused buyers.

The article also lists a separate real-time quote of $987. 62, highlighting near-term price volatility.

Earnings are slated for April 30, 2026.

Key facts:

- Shares fell 2.39% to $852.88, below 20-, 50-, and 200-day moving averages.

- Lilly to buy Ajax Therapeutics for up to $2.3 billion.

- Profluent collaboration worth up to $2.25 billion for AI DNA-editing medicines.

- Mounjaro and Zepbound made $36.5 billion, 56% of 2025 revenue.

- Projected price consolidation between $842.68 and $868.18 without rebound.

Why it matters: Lilly is doubling down on AI-enabled therapeutics and oncology to diversify beyond GLP-1 obesity/diabetes blockbusters. If the Ajax acquisition and Profluent partnership yield viable programs, Lilly reduces revenue concentration risk and strengthens long-term innovation leadership in AI medicine. If not, heavy dependence on Mounjaro/Zepbound leaves valuations vulnerable amid sector-wide selling. Near-term, watch earnings guidance and early milestones from the Profluent collaboration as signals of whether AI-designed DNA-editing can translate into pipeline value.

2. Elevance, Deloitte deploy agentic AI on Google ADK for payer workflows

AI in healthcare is shifting from model-building to responsible deployment in regulated workflows.

At Google Cloud Next, Elevance Health and Deloitte detailed a human-centered, multi-agent solution built on Google’s open-source Agent Development Kit to streamline payer-side operations such as provider inquiries, claim research, and correspondence.

The system synthesizes unstructured provider input and surfaces pre-assembled context for associates, keeping human judgment central while reducing handoffs.

Elevance executives said the design gets providers “90% of the way” to answering claim questions, speeding responses and letting clinicians refocus on care.

The effort aligns with a broader move toward agentic AI—goal-driven agents that plan, coordinate, and adapt across multi-step tasks—rather than purely reactive tools.

Elevance’s Danny Brakebill and Venkat Alladi, with Deloitte’s Balaji Ramdoss, emphasized responsible AI governance and accelerating time to value.

Framed as augmentation rather than replacement, the approach shows how payer workflows can adopt automation without sacrificing trust, accuracy, or empathy.

Key facts:

- Elevance Health and Deloitte built a multi-agent solution on Google’s Agent Development Kit.

- The tool synthesizes unstructured provider data and pre-assembles context for associates.

- Elevance says it gets providers “90% of the way” to answering claim questions.

- Focus area: provider inquiries, claim research, and correspondence in payer operations.

- Leaders involved: Danny Brakebill, Venkat Alladi, and Balaji Ramdoss.

Why it matters: Augmenting payer workflows with multi-agent, human‑centered AI can cut administrative drag and speed provider responses to members’ needs. Providers and patients benefit from faster resolution; payers gain scale while retaining oversight. Building on an open-source framework may ease adoption across fragmented systems. Watch for measurable gains in turnaround time, error rates, and auditability—and for robust governance to prevent over‑automation and protect trust.